Information for Metastatic Breast Cancer
Systemic Treatment for Metastatic Breast Cancer
Possible Treatment Option for Metastatic Breast Cancer
Subtype of Breast Cancer | Possible Treatment Option | Categories of Medication | Medication Name |
|---|---|---|---|
Hormone receptor-
positive breast cancer | Hormonal therapy | Selective estrogen receptor modulator | • Tamoxifen • Toremifene |
Selective estrogen receptor degrader (SERD) | • Fulvestrant | ||
Aromatase inhibitors | • Anastrozole • Exemestane • Letrozole | ||
Targeted therapy for
hormone receptor-positive | Cyclin-dependent kinase 4 and 6
inhibitors (CDK 4/6 inhibitors) | • Palbociclib • Ribociclib • Abemaciclib | |
Mammalian target of rapamycin
(mTOR) inhibitors | • Everolimus | ||
HER2 receptor-positive
breast cancer | Anti-HER2 therapy | HER2 receptor antagonist | • Trastuzumab • Pertuzumab |
Pertuzumab: HER 2 receptor antagonist Trastuzumab: HER2 receptor antagonist Hyaluronidase-zzxf: Endoglycoside | Pertuzumab, trastuzumab
and hyaluronidase-zzxf | ||
Tyrosine kinase inhibitors | • Tucatinib • Neratinib • Lapatinib | ||
HER2 antibody-drug conjugate | • Ado-trastuzumab entansine • Fam-trastuzumab deruxtecan | ||
Triple negative
breast cancer | Chemotherapy | Anti-microtubule agents | • Paclitaxel • Docetaxel • Eribulin • Vinorelbine • Ixabepilone |
Anthracyclines | • Doxorubicin • Epirubicin • Liposomal doxorubicin | ||
Alkylating agents | • Carboplatin • Cisplatin • Cyclophosphamide | ||
Antimetabolites | • Capecitabine • Gemcitabine • Fluorouracil • Methotrexate | ||
Immunotherapy | Programmed death-ligand 1 (PD-L1) inhibitor | • Atezolizumab • Pembrolizumab | |
BRCA gene changes
(mutation) | Targeted therapy for BRCA gene changes | Poly (ADP-ribose) polymerase (PARP) Inhibitors | • Olaparib • Talazoparib • Rucaparib • Veliparib • Niraparib |
